explore -WSS

explore

author：hotspot 2025-09-07 11:15:11 - browse：88417

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： U.K. sequencing study surfaces new findings about tumor DNA

focus

WSS

FDA sets aggressive timeline for overhauling inspection procedures

New weight loss drugs work. But how can they best be used?

High breast density mammograms need follow

JPM: CVS says Medicare Advantage patients are impacting profits

Ahead of JPM, here's who's profiting most in health care

Dog Aging Project founders on what lies ahead after losing funding

knowledge

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

There's an unseen cost to disruptive road

Novavax promises a turnaround & Lilly roils the obesity market

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Activists slam private health insurers over coverage restrictions

FDA endorses new sterilization method for medical devices

As demand for Covid shots wanes, Moderna seeks its next success

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Duchenne breakthrough therapy leaves behind pioneering families

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Wikipedia

The biotech scorecard for Q1: 17 stock

Inaction leaves children at risk from dangerous chemotherapy drug

Pumping milk in bathrooms at health conferences is common

New weight loss drugs work. But how can they best be used?

3 trends to watch in health tech's hiring outlook for 2024

FDA endorses new sterilization method for medical devices

Wikipedia

focus

explore

hotspot